JP2009540803A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540803A5
JP2009540803A5 JP2009515683A JP2009515683A JP2009540803A5 JP 2009540803 A5 JP2009540803 A5 JP 2009540803A5 JP 2009515683 A JP2009515683 A JP 2009515683A JP 2009515683 A JP2009515683 A JP 2009515683A JP 2009540803 A5 JP2009540803 A5 JP 2009540803A5
Authority
JP
Japan
Prior art keywords
polypeptide
cancer
polynucleotide
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009515683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540803A (ja
JP5564249B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/001134 external-priority patent/WO2007147265A1/en
Publication of JP2009540803A publication Critical patent/JP2009540803A/ja
Publication of JP2009540803A5 publication Critical patent/JP2009540803A5/ja
Application granted granted Critical
Publication of JP5564249B2 publication Critical patent/JP5564249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009515683A 2006-06-23 2007-06-22 癌に関与するポリヌクレオチド配列およびポリペプチド配列 Expired - Fee Related JP5564249B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81582906P 2006-06-23 2006-06-23
US60/815,829 2006-06-23
US87447106P 2006-12-13 2006-12-13
US60/874,471 2006-12-13
PCT/CA2007/001134 WO2007147265A1 (en) 2006-06-23 2007-06-22 Polynucleotides and polypeptide sequences involved in cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014024778A Division JP5589149B2 (ja) 2006-06-23 2014-02-12 癌に関与するポリヌクレオチド配列およびポリペプチド配列

Publications (3)

Publication Number Publication Date
JP2009540803A JP2009540803A (ja) 2009-11-26
JP2009540803A5 true JP2009540803A5 (enExample) 2010-08-05
JP5564249B2 JP5564249B2 (ja) 2014-07-30

Family

ID=38833043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009515683A Expired - Fee Related JP5564249B2 (ja) 2006-06-23 2007-06-22 癌に関与するポリヌクレオチド配列およびポリペプチド配列
JP2014024778A Expired - Fee Related JP5589149B2 (ja) 2006-06-23 2014-02-12 癌に関与するポリヌクレオチド配列およびポリペプチド配列

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014024778A Expired - Fee Related JP5589149B2 (ja) 2006-06-23 2014-02-12 癌に関与するポリヌクレオチド配列およびポリペプチド配列

Country Status (8)

Country Link
US (4) US8216582B2 (enExample)
EP (3) EP2032701B1 (enExample)
JP (2) JP5564249B2 (enExample)
AU (1) AU2007262635B2 (enExample)
CA (1) CA2655933C (enExample)
DK (1) DK2032701T3 (enExample)
ES (1) ES2444695T3 (enExample)
WO (1) WO2007147265A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
US20120128661A1 (en) * 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
JP2010533714A (ja) * 2007-07-16 2010-10-28 ポニアード ファーマシューティカルズ, インコーポレイテッド ピコプラチンのための経口製剤
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2471950B1 (en) * 2009-08-24 2015-04-01 National University Corporation Kanazawa University Detection of digestive system cancer by means of gene expression profiling
WO2011054112A1 (en) * 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體1抗體類和免疫共軛物類及彼等之用途
EP2603796B1 (en) 2010-08-13 2016-05-25 Arizona Board of Regents, a body corporate acting on behalf of Arizona State University Biomarkers for the early detection of breast cancer
MY166040A (en) * 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9297813B2 (en) * 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
JP6294221B2 (ja) 2011-03-31 2018-03-14 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原1に対する抗体およびその抗原結合性フラグメント
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
FR2984364A1 (fr) * 2011-12-20 2013-06-21 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer de l'ovaire
TR201908872T4 (tr) 2012-01-09 2019-07-22 Adc Therapeutics Sa Üçlü negatif meme kanserini tedavi etmek için ajanlar.
WO2013177060A2 (en) * 2012-05-20 2013-11-28 Trustees Of Boston University Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
KR20160097336A (ko) * 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-dpep3 항체 및 이의 사용 방법
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US11860141B2 (en) 2017-08-14 2024-01-02 Quest Diagnostics Investments Llc Detection and quantitation of guanidinoacetate, creatine, and creatinine by mass spectrometry

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) * 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
GB8601646D0 (en) 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US5585279A (en) * 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
JPH07110852B2 (ja) 1989-12-28 1995-11-29 ジ・アップジョン・カンパニー 二芳香族置換抗aids化合物
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5708022A (en) * 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
AU4017695A (en) 1994-10-28 1996-05-23 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
NZ502303A (en) 1997-06-18 2002-02-01 Ulrich J Krull Nucleic acid biosensor system & diagnostic use
WO1999031513A1 (en) 1997-12-15 1999-06-24 Lakowicz Joseph R Method and composition for characterizing a sample containing a sample lipid and an assay kit
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
CA2328405A1 (en) * 1998-05-13 1999-11-18 Ludwig Institute For Cancer Research Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
ES2299244T3 (es) * 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020106678A1 (en) 1998-06-30 2002-08-08 Robishaw Janet D. cDNA clones encoding human G protein gamma subunits
US6562823B1 (en) 1998-07-02 2003-05-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6288221B1 (en) * 1998-08-20 2001-09-11 Duke University Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction
AU6136599A (en) 1998-09-08 2000-03-27 University Of Maryland At Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6806089B1 (en) * 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
WO2000023448A1 (en) 1998-10-22 2000-04-27 Moheno Phillip B B Novel pterin antineoplastic agents
AU3268500A (en) 1999-03-19 2000-10-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6872519B1 (en) * 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20030024579A1 (en) 1999-07-07 2003-02-06 Blackmore Donald Ian Diverter valve
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001046209A1 (en) 1999-12-20 2001-06-28 Fluorrx, Inc. Fluorescent probes
US20030219806A1 (en) * 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US7585839B2 (en) * 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US20030215860A1 (en) * 2000-02-29 2003-11-20 Millennium Pharmaceuticals, Inc. Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
AU2001269836A1 (en) * 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
AU2002214531A1 (en) * 2000-07-03 2002-01-30 Curagen Corporation Proteins and nucleic acids encoding same
US20050053930A1 (en) * 2000-07-18 2005-03-10 David Anderson Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7030236B2 (en) 2001-03-09 2006-04-18 Mona Savitri Jhaveri Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
EP2280030A3 (en) * 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス, インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2002347428A1 (en) * 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040053824A1 (en) * 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
ATE483722T1 (de) 2001-08-31 2010-10-15 Btg Int Ltd Antikrebs-cyclopentaag chinazoline-derivate
PT1420809E (pt) 2001-08-31 2012-01-03 Btg Int Ltd Utilização de derivados de ciclopenta[g]quinazolina para tratamento de cancro
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
OA12812A (en) 2001-11-19 2006-07-10 Elan Pharm Inc (4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
EP1487870A2 (en) * 2002-01-09 2004-12-22 Université de Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
JP2005516072A (ja) * 2002-01-28 2005-06-02 ケラプラスト テクノロジーズ, リミテッド 生物活性ケラチンタンパク質
US6962910B2 (en) * 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
US20050095592A1 (en) 2002-02-13 2005-05-05 Jazaeri Amir A. Identification of ovarian cancer tumor markers and therapeutic targets
DE10206616A1 (de) * 2002-02-15 2003-09-04 Qiagen Gmbh Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen
JP2005533000A (ja) * 2002-03-05 2005-11-04 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム Mda−7に関与する免疫誘導を増強する方法
WO2003087768A2 (en) * 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
EP1575491A4 (en) * 2002-05-20 2006-09-27 Abgenix Inc TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1422242A1 (en) 2002-11-22 2004-05-26 Emory University Plastic and elastic protein copolymers
US20060247193A1 (en) * 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1635866A2 (en) * 2003-05-20 2006-03-22 Cellpep S.A. Modified antiviral peptides with increased activity and cell membrane affinity
US20070274947A1 (en) * 2003-05-21 2007-11-29 Young Aiping H Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
US20060078941A1 (en) 2003-06-09 2006-04-13 Santin Alessandro D Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
WO2006003352A1 (en) 2004-07-06 2006-01-12 Warwick Effect Polymers Limited Living radical polymerization initiator comprising a functional group capable of reacting with polyeptides or the like, comb polymer obtained therewith, polypeptide conjugates and drugs obtained therefrom
GB0318096D0 (en) * 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050147621A1 (en) * 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1697389A4 (en) * 2003-10-24 2008-12-24 Eisai R&D Man Co Ltd COMPOUNDS AND METHODS FOR TREATING ILLNESS AND SUFFERING TOLL-LIKE RECEPTOR 2 RELATED DISORDERS
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1756272A2 (en) * 2004-01-09 2007-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
US7655402B2 (en) 2004-02-06 2010-02-02 Wyeth Llc Diagnoses and therapeutics for cancer
EP1723428A2 (en) 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
CA2558155A1 (en) 2004-03-01 2005-09-09 Zvi Sidelman Casein derived peptides and therapeutic uses thereof
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
US8247371B2 (en) 2004-10-14 2012-08-21 Yale University Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
EP1814573B1 (en) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP2008526749A (ja) * 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド 自己アセンブリするペプチドナノファイバーを用いたpdgfの徐放性の送達
CN101133037B (zh) 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
JP2008532014A (ja) * 2005-02-24 2008-08-14 セマインズ,インコーポレイティド 生物試料を分類するための組成物及び方法
AU2006227379B2 (en) 2005-03-17 2011-10-20 President And Fellows Of Harvard College Synthesis of avrainvillamide, stephacidin B, and analogues thereof
FR2885525B1 (fr) * 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
NZ565063A (en) * 2005-06-13 2011-04-29 Cleveland Biolabs Inc Methods of protecting against apoptosis using lipopeptides
EP1912679A4 (en) 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのlxrモジュレーター
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US7494788B2 (en) * 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7820790B2 (en) * 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
GB0516058D0 (en) 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
GB0517293D0 (en) 2005-08-24 2005-10-05 Cancer Rec Tech Ltd Vectors and uses thereof
PL1931998T3 (pl) * 2005-09-15 2010-11-30 Alk Abello As Sposób ilościowego oznaczania alergenów
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007059108A2 (en) 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
WO2007061853A2 (en) 2005-11-23 2007-05-31 Merck & Co., Inc. Process for synthesizing 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative
KR101049859B1 (ko) 2007-11-28 2011-07-19 대한민국 N-말단 pI 값 조절에 의한 수용성 재조합 단백질 생산방법
CA2638833A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
JP5167155B2 (ja) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
JP5394074B2 (ja) 2006-03-10 2014-01-22 ワーウィック イフェクト ポリマーズ リミテッド ポリマー
WO2007110755A1 (en) 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
US8003607B2 (en) * 2006-04-20 2011-08-23 Kringle Pharma Inc. HGF precursor protein variant and active protein thereof
WO2007131191A2 (en) * 2006-05-05 2007-11-15 Perkinelmer Life And Analytical Sciences Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
CA2900402C (en) 2006-05-08 2018-01-16 Adaerata, Limited Partnership Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
NL1032064C2 (nl) * 2006-06-27 2008-01-02 Walraven Holding Bv J Van Pijpbeugel met trillingisolerende inlaag.
EP2041556A1 (en) 2006-06-28 2009-04-01 RGB Technologies AB A sensor kit and a system for detecting an analyte in a test environment
US8198046B2 (en) * 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008012362A2 (en) * 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8314221B2 (en) * 2006-09-07 2012-11-20 Laurence Claude Faure Pharmacodiagnostic test targeting oncology and neurodegeneration
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
DE102006051516A1 (de) * 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
ES2506090T3 (es) 2006-12-28 2014-10-13 Abbvie Inc. Inhibidores de la (ADP-ribosa) polimerasa
SG177959A1 (en) * 2007-01-09 2012-02-28 Cleveland Biolabs Inc Methods for increasing and mobilizing hematopoietic stem cells
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20080311145A1 (en) * 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
US20080306007A1 (en) * 2007-04-30 2008-12-11 Newcastle Innovation Limited Agents for prophylaxis or treatment of neurological related diseases and conditions
WO2008134761A2 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
US8143372B2 (en) * 2007-05-21 2012-03-27 Children's Hospital & Research Center Oakland Synthetic regulators of ferritin protein nanocage pores and methods of use thereof
WO2008151146A2 (en) * 2007-06-01 2008-12-11 Digitab, Inc. Peptide arrays and methods of use
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US9018138B2 (en) * 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
EP2185590A2 (en) * 2007-09-07 2010-05-19 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20110165223A1 (en) 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
JP5777510B2 (ja) * 2008-05-09 2015-09-09 エボニック コーポレイションEvonik Corporation 生物適合性及び生分解性のエラストマー性ポリマー
EP2306993B1 (en) 2008-05-26 2014-03-12 Universität Zürich Protamine/rna nanoparticles for immunostimulation
AU2009266793B2 (en) 2008-07-03 2012-12-20 Brickell Biotech, Inc. Antagonists of prostaglandin D2 receptors
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
AU2009277179A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010017479A1 (en) 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010060186A1 (en) * 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
WO2011054112A1 (en) 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1

Similar Documents

Publication Publication Date Title
JP2009540803A5 (enExample)
JP6630766B2 (ja) 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法
KR101146613B1 (ko) 간암에 대한 신규 바이오마커 및 그의 용도
EP2619321B1 (en) Biomarkers for differentiating melanoma from benign nevus in the skin
JP5224308B2 (ja) 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
KR101478826B1 (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
AU2010268389B2 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms
KR20130008899A (ko) 자궁내막증과 연관된 유전자 마커 및 이의 용도
KR101388711B1 (ko) 암 진단 마커로서의 보체 c9
KR101815253B1 (ko) 간 섬유화 진단용 바이오마커 cxcl14
EP2581745B1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
CN108139404B (zh) 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测
KR101289454B1 (ko) 소세포폐암 및 비소세포폐암 진단 마커로서의 보체 c9
US11714089B2 (en) Combination of markers for diagnosing cancer
KR100721507B1 (ko) 위암 진단 마커로서의 Mac-2BP
KR20200025706A (ko) Fgf 21을 포함하는 갑상선 암 진단 또는 갑상선 암 예후 예측용 바이오마커 조성물
KR101516716B1 (ko) 간 섬유화 진단용 바이오마커 rorc
JP2017529074A (ja) 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
KR101515210B1 (ko) 간 섬유화 진단용 바이오마커 elk3
KR100983386B1 (ko) 난소암 진단을 위한 agr-2의 신규한 용도
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR100931997B1 (ko) 간세포암 종양 마커로서의 klk-5 유전자 및 이를 이용한간세포암 진단 방법
KR20240161980A (ko) 갑상선암의 진단을 위한 신규한 바이오 마커
JP2026502556A (ja) エクソソームを用いた扁平上皮細胞肺癌の診断又は予後予測用バイオマーカー及びその用途
KR20160096841A (ko) 간암의 진단 또는 예후 바이오 마커 및 그의 용도